Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $) In Thousands, unless otherwise specified	6 Months Ended
	Jun. 30, 2012	Jun. 30, 2011
Cash flows from operating activities:
Net income	$ 16,784	$ 12,500
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Change in fair value of warrant liability	(2,649)	(10,807)
Depreciation and amortization	5,501	4,964
Amortization of deferred financing costs	530	1,987
Accretion of debt discount	2,031	2,657
Gain on sale of assets	(2,475)	(1,428)
Stock compensation expense	5,877	2,698
Deferred income tax provision	746	(160)
Excess tax benefit related to share-based awards	(518)	(229)
Non-cash loss on extinguishment of debt	6,386	3,225
Change in current assets and liabilities:
Accounts receivable	2,175	(11,048)
Inventories	(3,089)	(8,429)
Accrued liabilities	604	(1,152)
Interest payable	(1,004)	(30)
Accounts payable	(1,992)	1,254
Other current assets	(2,321)	(1,806)
Income taxes payable	(2,397)	2,414
Net cash provided by (used in) operating activities	22,073	(3,390)
Cash flows from investing activities:
Capital expenditures	(9,478)	(3,657)
Proceeds from sale of assets	2,618	2,279
Purchase of patents and other intangible assets	(29)	(220)
Net cash used in investing activities	(6,889)	(1,598)
Cash flows from financing activities:
Repayments of indebtedness	(51,535)	(32,871)
Excess tax benefit related to share-based awards	518	229
Purchase of treasury stock	(490)	(199)
Proceeds from sale of common stock		29,438
Proceeds from exercise of stock options	131	109
Proceeds from exercise of warrants	263	4,581
Debt issuance costs		(1,000)
Net cash provided by (used in) financing activities	(51,113)	287
Effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency	(28)	(25)
Net decrease in cash and cash equivalents	(35,957)	(4,726)
Cash and cash equivalents at the beginning of period	46,682	19,863
Cash and cash equivalents at the end of period	$ 10,725	$ 15,137